Zhejiang Sunflower Light Energy (300111) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Sunflower Light Energy (300111) has a cash flow conversion efficiency ratio of 0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥2.42 Million ≈ $354.23K USD) by net assets (CN¥826.15 Million ≈ $120.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zhejiang Sunflower Light Energy - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Zhejiang Sunflower Light Energy's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 300111 liabilities breakdown for a breakdown of total debt and financial obligations.
Zhejiang Sunflower Light Energy Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Sunflower Light Energy ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allied Circuit Co Ltd
TWO:8155
|
-0.016x |
|
Solusi Sinergi Digital Tbk PT
JK:WIFI
|
0.018x |
|
Fujian Yongfu Power Engineering Co Ltd Class A
SHE:300712
|
0.098x |
|
Hextar Global Bhd
KLSE:5151
|
0.160x |
|
Tanla Platforms Limited
NSE:TANLA
|
0.074x |
|
Sinoma Energy Conservation Ltd
SHG:603126
|
-0.039x |
|
Ningbo Exciton Technology Co Ltd
SHE:300566
|
0.062x |
|
Vatti Corp Ltd
SHE:002035
|
0.032x |
Annual Cash Flow Conversion Efficiency for Zhejiang Sunflower Light Energy (2007–2024)
The table below shows the annual cash flow conversion efficiency of Zhejiang Sunflower Light Energy from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see Zhejiang Sunflower Light Energy (300111) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥822.98 Million ≈ $120.43 Million |
CN¥31.44 Million ≈ $4.60 Million |
0.038x | +977.53% |
| 2023-12-31 | CN¥809.53 Million ≈ $118.46 Million |
CN¥2.87 Million ≈ $419.94K |
0.004x | -93.91% |
| 2022-12-31 | CN¥414.84 Million ≈ $60.70 Million |
CN¥24.16 Million ≈ $3.54 Million |
0.058x | -75.93% |
| 2021-12-31 | CN¥410.25 Million ≈ $60.03 Million |
CN¥99.27 Million ≈ $14.53 Million |
0.242x | +23.02% |
| 2020-12-31 | CN¥271.06 Million ≈ $39.66 Million |
CN¥53.31 Million ≈ $7.80 Million |
0.197x | -42.26% |
| 2019-12-31 | CN¥171.75 Million ≈ $25.13 Million |
CN¥58.50 Million ≈ $8.56 Million |
0.341x | -6.55% |
| 2018-12-31 | CN¥177.16 Million ≈ $25.92 Million |
CN¥64.58 Million ≈ $9.45 Million |
0.365x | +132.94% |
| 2017-12-31 | CN¥1.31 Billion ≈ $192.13 Million |
CN¥205.46 Million ≈ $30.07 Million |
0.156x | -44.26% |
| 2016-12-31 | CN¥1.30 Billion ≈ $190.34 Million |
CN¥365.14 Million ≈ $53.43 Million |
0.281x | +57.08% |
| 2015-12-31 | CN¥1.27 Billion ≈ $185.22 Million |
CN¥226.22 Million ≈ $33.10 Million |
0.179x | +90.07% |
| 2014-12-31 | CN¥1.21 Billion ≈ $176.79 Million |
CN¥113.60 Million ≈ $16.62 Million |
0.094x | +56.31% |
| 2013-12-31 | CN¥1.16 Billion ≈ $169.84 Million |
CN¥69.82 Million ≈ $10.22 Million |
0.060x | -83.24% |
| 2012-12-31 | CN¥1.13 Billion ≈ $164.96 Million |
CN¥404.72 Million ≈ $59.22 Million |
0.359x | +362.17% |
| 2011-12-31 | CN¥1.49 Billion ≈ $217.98 Million |
CN¥115.72 Million ≈ $16.93 Million |
0.078x | -45.63% |
| 2010-12-31 | CN¥1.66 Billion ≈ $242.74 Million |
CN¥237.02 Million ≈ $34.68 Million |
0.143x | +6.92% |
| 2009-12-31 | CN¥616.58 Million ≈ $90.23 Million |
CN¥82.39 Million ≈ $12.06 Million |
0.134x | +141.52% |
| 2008-12-31 | CN¥409.97 Million ≈ $59.99 Million |
CN¥-131.96 Million ≈ $-19.31 Million |
-0.322x | +73.14% |
| 2007-12-31 | CN¥103.31 Million ≈ $15.12 Million |
CN¥-123.82 Million ≈ $-18.12 Million |
-1.199x | -- |
About Zhejiang Sunflower Light Energy
Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally. It offers clarithromycin API and tablets, anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, Mycoplasma pne… Read more